Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma - PubMed (original) (raw)
. 2005 Jul 1;65(13):5898-906.
doi: 10.1158/0008-5472.CAN-04-4125.
Xianfeng Li, Xia Tong, Daniel Santos, Takemi Otsuki, Laurence Catley, Olivier Tournilhac, Klaus Podar, Teru Hideshima, Robert Schlossman, Paul Richardson, Nikhil C Munshi, Mohammad Luqman, Kenneth C Anderson
Affiliations
- PMID: 15994968
- DOI: 10.1158/0008-5472.CAN-04-4125
Free article
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
Yu-Tzu Tai et al. Cancer Res. 2005.
Free article
Abstract
Monoclonal antibodies (mAb) directed against lineage-specific B-cell antigens have provided clinical benefit for patients with hematologic malignancies, but to date no antibody-mediated immunotherapy is available for multiple myeloma. In the present study, we assessed the efficacy of a fully human anti-CD40 mAb CHIR-12.12 against human multiple myeloma cells. CHIR-12.12, generated in XenoMouse mice, binds to CD138-expressing multiple myeloma lines and freshly purified CD138-expressing cells from >80% multiple myeloma patients, as assessed by flow cytometry. Importantly, CHIR-12.12 abrogates CD40L-induced growth and survival of CD40-expressing patient multiple myeloma cells in the presence or absence of bone marrow stromal cells (BMSC), without altering constitutive multiple myeloma cell proliferation. Immunoblotting analysis specifically showed that PI3-K/AKT, nuclear factor-kappaB (NF-kappaB), and extracellular signal-regulated kinase activation induced by CD40L (5 mug/mL) was inhibited by CHIR-12.12 (5 mug/mL). Because CD40 activation induces multiple myeloma cell adhesion to both fibronectin and BMSCs, we next determined whether CHIR-12.12 inhibits this process. CHIR-12.12 decreased CD40L-induced multiple myeloma cell adhesion to fibronectin and BMSCs, whereas control human IgG1 did not. Adhesion of multiple myeloma cells to BMSCs induces interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) secretion, and treatment of multiple myeloma cells with CD40L further enhanced adhesion-induced cytokine secretion; conversely, CHIR-12.12 blocks CD40L-enhanced IL-6 and VEGF secretion in cocultures of multiple myeloma cells with BMSCs. Finally, CHIR-12.12 triggered lysis of multiple myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) but did not induce ADCC against CD40-negative multiple myeloma cells, confirming specificity against CD40-expressing multiple myeloma cells. These results provide the preclinical rationale for clinical trials of CHIR-12.12 to improve patient outcome in multiple myeloma.
Similar articles
- Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC. Tai YT, et al. Cancer Res. 2004 Apr 15;64(8):2846-52. doi: 10.1158/0008-5472.can-03-3630. Cancer Res. 2004. PMID: 15087402 Retracted. - Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Tai YT, et al. Cancer Res. 2005 Dec 15;65(24):11712-20. doi: 10.1158/0008-5472.CAN-05-1657. Cancer Res. 2005. PMID: 16357183 - The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells.
Teoh G, Urashima M, Greenfield EA, Nguyen KA, Lee JF, Chauhan D, Ogata A, Treon SP, Anderson KC. Teoh G, et al. J Clin Invest. 1998 Mar 15;101(6):1379-88. J Clin Invest. 1998. PMID: 9502780 Free PMC article. - Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Hideshima T, et al. Semin Oncol. 2001 Dec;28(6):607-12. doi: 10.1016/s0093-7754(01)90033-8. Semin Oncol. 2001. PMID: 11740818 Review. - Novel biologically based therapies for myeloma.
Anderson KC. Anderson KC. Cancer J. 2001 Jul-Aug;7 Suppl 1:S19-23. Cancer J. 2001. PMID: 11504280 Review.
Cited by
- New frontiers in the treatment of multiple myeloma.
Hwang JJ, Ghobrial IM, Anderson KC. Hwang JJ, et al. ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236. ScientificWorldJournal. 2006. PMID: 17160337 Free PMC article. Review. - Advances in the assessment and control of the effector functions of therapeutic antibodies.
Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Jiang XR, et al. Nat Rev Drug Discov. 2011 Feb;10(2):101-11. doi: 10.1038/nrd3365. Nat Rev Drug Discov. 2011. PMID: 21283105 Review. - Expression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastoris.
Zhan Y, Wei Y, Chen P, Zhang H, Liu D, Zhang J, Liu R, Chen R, Zhang J, Mo W, Zhang X. Zhan Y, et al. BMC Biotechnol. 2016 Jan 25;16:8. doi: 10.1186/s12896-016-0237-1. BMC Biotechnol. 2016. PMID: 26809818 Free PMC article. - Novel immunotherapies.
Yi Q. Yi Q. Cancer J. 2009 Nov-Dec;15(6):502-10. doi: 10.1097/PPO.0b013e3181c51f0d. Cancer J. 2009. PMID: 20010170 Free PMC article. Review. - Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma.
Zhou FL, Zhang WG, Chen G, Zhao WH, Cao XM, Chen YX, Tian W, Liu J, Liu SH. Zhou FL, et al. Cancer Immunol Immunother. 2006 Aug;55(8):910-7. doi: 10.1007/s00262-005-0074-x. Epub 2005 Sep 29. Cancer Immunol Immunother. 2006. PMID: 16193335 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous